12:56 PM EDT, 08/21/2025 (MT Newswires) -- Krystal Biotech ( KRYS ) said Thursday that it will advance inhaled immunotherapy KB707 as a priority program for non-small cell lung cancer.

The company said it plans to meet with the US Food and Drug Administration in October to review possible registration routes for inhaled KB707.

At the American Society of Clinical Oncology's annual meeting, the company said that inhaled KB707 achieved a 36% objective response rate in heavily pre-treated NSCLC patients. The treatment was generally well tolerated with no grade 4 or 5 adverse events reported, the company said.

With its focus shifting to inhaled delivery, Krystal said it paused enrollment in its OPAL-1 phase 1/2 study evaluating intratumoral KB707 in solid tumors but will continue monitoring patients already enrolled.

Price: 145.81, Change: -0.06, Percent Change: -0.04